<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01371045</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00024880</org_study_id>
    <nct_id>NCT01371045</nct_id>
  </id_info>
  <brief_title>Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs</brief_title>
  <official_title>Hormonal and Metabolic Responses to Oral Glucose During Somatostatin Analog Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effect of long-acting somatostatin analog
      medications, taken by patients with acromegaly or carcinoid syndrome, on growth hormone in
      comparison to healthy controls who are not receiving the medication in order to see whether
      or not the medication makes the oral glucose test less accurate. The Oral Glucose Tolerance
      Test (OGTT) is a standard test to measure growth hormone secretion. By comparing GH responses
      in non-acromegaly subjects taking somatostatin analog treatment, the relative contribution of
      the medication and the underlying disease state can be analyzed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be informed of the study and after providing written informed consent, subjects
      will be asked to undergo a 2-hour oral glucose tolerance test (ingestion of 75g glucose with
      subsequent timed assessment of growth hormone, glucose, insulin and related binding
      proteins.) Baseline assessment of hormones that may contribute to the results will be drawn,
      prior to performing the test. Patients will be asked to complete one visit total to
      participate in this trial.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Growth hormone response to OGTT</measure>
    <time_frame>2 hours</time_frame>
    <description>assessment of the validity of GH suppression during somatostatin analog treatment in acromegaly and non-acromegaly subjects</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Acromegaly</arm_group_label>
    <description>Patients carrying the diagnosis of acromegaly who are on long-acting somatostatin for at least 3 months prior to study enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carcinoid Syndrome</arm_group_label>
    <description>Patients carrying a diagnosis of carcinoid syndrome who are taking long-acting somatostatin for at least 3 months prior to study enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Glucose Tolerance Test (OGTT)</intervention_name>
    <description>An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.</description>
    <arm_group_label>Acromegaly</arm_group_label>
    <arm_group_label>Carcinoid Syndrome</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood will be drawn (approx. 64cc) to gather baseline hormone and metabolic panels. Blood
      will again be collected (approx. 36cc) during the Oral Glucose Tolerance Test.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Enrollment will include subjects diagnosed with acromegaly or carcinoid syndrome who are
        taking long-acting somatostatin analogs for at least three months prior to study
        enrollment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of acromegaly or carcinoid syndrome

          -  Treatment with somatostatin analog therapy (must have established a stable dose of
             three or more injections on the same dose prior to study enrollment)

          -  Healthy control subjects

        Exclusion Criteria:

          -  Diagnosis of Diabetes Mellitus (Type 1 or Type 2)

          -  Use of medication for the treatment of insulin resistance or diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John D Carmichael, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hershel Bhadsavle</last_name>
    <phone>(310) 423-2830</phone>
    <email>hershel.bhadsavle@cshs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Billy Gellepis</last_name>
    <phone>310-423-3395</phone>
    <email>Billy.Gellepis@cshs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center, Pituitary Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Carmichael, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Earll JM, Sparks LL, Forsham PH. Glucose suppression of serum growth hormone in the diagnosis of acromegaly. JAMA. 1967 Aug 21;201(8):628-30.</citation>
    <PMID>5006772</PMID>
  </reference>
  <reference>
    <citation>Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S; Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010 Jul;95(7):3141-8. doi: 10.1210/jc.2009-2670. Epub 2010 Apr 21.</citation>
    <PMID>20410227</PMID>
  </reference>
  <reference>
    <citation>Vierhapper H, Heinze G, Gessl A, Exner M, Bieglmayr C. Use of the oral glucose tolerance test to define remission in acromegaly. Metabolism. 2003 Feb;52(2):181-5.</citation>
    <PMID>12601629</PMID>
  </reference>
  <reference>
    <citation>Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab. 2009 Feb;94(2):523-7. doi: 10.1210/jc.2008-1371. Epub 2008 Nov 25.</citation>
    <PMID>19033371</PMID>
  </reference>
  <reference>
    <citation>Rubeck KZ, Madsen M, Andreasen CM, Fisker S, Frystyk J, Jørgensen JO. Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery. Eur J Endocrinol. 2010 Nov;163(5):717-26. doi: 10.1530/EJE-10-0640. Epub 2010 Sep 2.</citation>
    <PMID>20813787</PMID>
  </reference>
  <reference>
    <citation>ROTH J, GLICK SM, YALOW RS, BERSON SA. Secretion of human growth hormone: physiologic and experimental modification. Metabolism. 1963 Jul;12:577-9.</citation>
    <PMID>13975314</PMID>
  </reference>
  <reference>
    <citation>Arafat AM, Möhlig M, Weickert MO, Perschel FH, Purschwitz J, Spranger J, Strasburger CJ, Schöfl C, Pfeiffer AF. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab. 2008 Apr;93(4):1254-62. doi: 10.1210/jc.2007-2084. Epub 2008 Jan 2.</citation>
    <PMID>18171702</PMID>
  </reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2011</study_first_submitted>
  <study_first_submitted_qc>June 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2011</study_first_posted>
  <last_update_submitted>June 9, 2011</last_update_submitted>
  <last_update_submitted_qc>June 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>John Carmichael, M.D.</name_title>
    <organization>Cedars-Sinai Medical Center</organization>
  </responsible_party>
  <keyword>Acromegaly</keyword>
  <keyword>Growth Hormone</keyword>
  <keyword>Carcinoid Syndrome</keyword>
  <keyword>Somatostatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

